Jon Saxe - SciClone Pharmaceuticals Insider

Independent Chairman of the Board

Mr. Jon S. Saxe J.D., is an Independent Chairman of the Board of SciClone Pharmaceuticals, Inc., since July 29, 2009. He has served as the Chairman of our Board of Directors since July 2009 and as a Director since August 2000. Mr. Saxe was President of PDL BioPharma, Inc. from 1995 to early 1999. From 1993 to 1995, Mr. Saxe was President of Saxe Associates, Inc., consultants to VC firms and biotechnology, diagnostic, and pharmaceutical companies. He was the President and CEO of Synergen, Inc., a biotechnology company acquired by Amgen, from 1989 to 1993. Mr. Saxe is former Vice President, Licensing and Corporationrationrate Development and Head of Patent Law for HoffmannLaRoche Inc., where he worked for almost 30 years
Age: 78  Chairman Since 2009      
650-358-3456  www.sciclone.com
Jon Saxe EducationSaxe received his B.S. Ch.E. from CarnegieMellon University, his J.D. from George Washington University School of Law and his LL.M. from New York University School of Law. He serves as a director of other public and private companies, including Durect Corporationrationration and as Chairman of VistaGen Therapeutics, Inc.

Management Efficiency

The company has return on total asset (ROA) of 0.15 % which means that it generated profit of $0.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.18 % meaning that it created $0.18 on every $100 dollars invested by stockholders.
The company currently holds 1.65 M in liabilities with Debt to Equity (D/E) ratio of 0.01 which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals Inc has Current Ratio of 7.33 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 13 records

CHAIRMAN Since

Mr CBEQuintiles Transnational Holding
N/A
Ciaran MurrayICON Public Limited Company
2011
Herve HoppenotIncyte Corporation
2015
Dennis GillingsQuintiles Transnational Holding
2015
P VagelosRegeneron Pharmaceuticals Inc
1995
CBE GillingsQuintiles Transnational Holding
N/A
Richard SchutterIncyte Corporation
2004
William RastetterIllumina Inc
2005
Roy VagelosRegeneron Pharmaceuticals Inc
1995
Thomas LynchICON Public Limited Company
2016
Julian BakerIncyte Corporation
2015
Jay FlatleyIllumina Inc
2016
John ClimaxICON Public Limited Company
2010

Entity Summary

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals Inc (SCLN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 590 people. SciClone Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare with concentration in Pharmaceuticals And Biosciences.
Did you try this?
Run Portfolio Rebalancing Now
   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Hide  View All  Next  Launch Portfolio Rebalancing
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add SciClone Pharmaceuticals Inc to your portfolio
Top Management
SciClone Pharmaceuticals Leadership Team
Charles Meng, VP
Richard Hawkins, Director
Gregg Lapointe, Director, MBA
Hong Zhao, CEO
Wilson Cheung, CFO
Nancy Chang, Director, Ph.D
Anthony Lapointe, Director, MBA
Lan Xie, CFO, MBA
Raymond Low, President, MBA
Robert King, President, Ph.D
Simon Li, Director, MBA
Min Yin, VP
Jon Saxe, Chairman
Friedhelm Blobel, CEO, Ph.D
Stock Performance
SciClone Pharmaceuticals Performance Indicators